Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00229697 · ClinicalTrials.gov registry record · Phase 2
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 317
- Enrollment target
NCT00229697 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 317 participants.
The verdict
NCT00229697, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 317 participants
- Enrollment target
Study Summary
This study is being carried out to see if ZD1839 is effective in treating metastatic breast cancer in combination with Nolvadex, and if so, how it compares with Nolvadex alone.
Interventions
- DRUG Tamoxifen
- DRUG Gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2003-10 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00229697
The ClinicalTrials.gov registry entry for NCT00229697 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 317 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tamoxifen is the first listed.
NCT00229697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00229697 about?
NCT00229697 is a clinical study titled "Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study". This study is being carried out to see if ZD1839 is effective in treating metastatic breast cancer in combination with Nolvadex, and if so, how it compares with Nolvadex alone.
What is the current status of trial NCT00229697?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 317 participants. The study started on 2003-10. Estimated completion is 2015-06.
What interventions are being tested in trial NCT00229697?
The interventions under investigation include: Tamoxifen (DRUG), Gefitinib (DRUG).
Who is sponsoring clinical trial NCT00229697?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.